Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

Taylor, M., Antonia, S., Bendell, J., Calvo, E., Jäger, D., de Braud, F., … Eder, J. P. (2015). Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Journal for ImmunoTherapy of Cancer, 3(S2). https://doi.org/10.1186/2051-1426-3-s2-p376